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Summary
Sera from human immunodeficiency virus type 1 (HIV-1)-infected and -noninfected individuals
were screened for antibodies that could bind to native T cell differentiation antigens. Antibodies
that could immunoprecipitate CD43 (sialophorin, leukosialin) from a T celllymphoma line were
detected in sera from 27% of patients, and antibodies that could bind specifically to transfected
cells expressing CD43 were detected in 47% of patients. The anti-CD43 antibodies were related
to HIV-1 infection in that no patients with other chronic viral infections or systemic lupus
erythematosus contained such antibodies in their sera. The anti-CD43 autoantibodies bound
to a partially sialylated form ofCD43 expressed by normal human thymocytes, but not by normal,
circulatingT lymphocytes. However, the determinant(s) recognized by the anti-CD43 autoantibodies
was present on a large proportion of circulating T lymphocytes, but masked from antibody
recognition by sialic acid residues . These results demonstrate that HIV-1 infection is specifically
associated with the production of autoantibodies that bind to a native T cell surface antigen .
T
he severe immunodeficiency associated with HIV-1 in-
fection is believed to result primarily from depletion,
and to some degree, dysfunction of CD4+ T lymphocytes
(1) . Many individuals infected by HIV-1 have serum antiT
lymphocyte antibodies (2-9), and it has been suggested that
such antibodies contribute to the CD4+ lymphocyte abnor-
malities ofAIDS. Antilymphocyte antibodies that mediate
complement-induced lysis of allogeneic T cells (2-4, 7, 8)
or suppress mitogen-induced proliferation of allogeneic CD4+
lymphocytes (8) have been detected in sera from HIV-1-infected
individuals . Moreover, circulating T lymphocytes coated by
autologous Ig (surface Ig+ T cells) have been detected in a
substantial proportion of infected patients (10-12) . Such sur-
face Ig+ T cells can appear early in the course of HIV-1 in-
fection, before decrements in the absolute CD4+ lympho-
cytes counts (12).
Despite the potential immunosuppressive effects ofantilym-
phocyte antibodies, their actual contribution to the im-
munopathogenesis of AIDS remains controversial . One
problem has been the difficulty in identifying specific T cell
surface antigens recognized by such antibodies. Although
serum antibodies that bind to soluble, recombinant forms
ofCD4 (sCD4) appear specific for HIV-1 infection, (13-15),
they do not bind to nativeCD4 on lymphocytes (13) . Other
lymphocyte-derived proteins that react with antibodies from
HIV-1 + sera (8, 16) have been described, but the identities
of these proteins and their cellular location (i.e., cell surface
vs. intracellular) remain uncertain .
In the present study, we show that many HIV-1-infected
individuals make autoantibodies that bind specifically to the
T cell surface antigen CD43 . CD43, also known as sialo-
phorin (17) or leukosialin (18), is a heavily sialylated gly-
coprotein expressed on the surface of virtually all thymocytes
and T lymphocytes (19, 20) . The anti-CD43 autoantibodies
from HIV-1-infected individuals recognize a partially sialylated
form ofCD43 that is present on normal human thymocytes
but not on mature, circulating T lymphocytes . The poten-
tial significance of these results is discussed in the context
of recent insights into the role ofCD43 inimmune physiology .
Materials and Methods
Cells and CellLines.
￿
Normal humanPBMC were obtained from
heparinized blood samples from healthy donors and prepared by
Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) den-
sity centrifugation . PBMC were treated with 5 hg/ml of PHA
(Sigma Chemical Co., St . Louis, MO) for 3 d and then with 20
U/ml human rIl-2 (Cetus Corp., Emeryville, CA) for 5 d to obtain
T lymphoblasts . Human thymocytes were obtained from infants
undergoing corrective cardiac surgery at the New England Med-
ical Center Hospital . The T cell lymphomas cell line SupT1 (21)
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Philadelphia,PA . TheTlymphoblasts andtheSupT1 cell line were
grown in RPMI 1640 media (containing10%FCS [Hyclonelabora-
tories, Logan, UT] supplemented with glutamine [2 mM], peni-
cillin [100 U/ml], andstreptomycin [100 Fcg/ml]) . COS cells used
for transfection studies were maintained in similar media, sub-
stituting gentamicin sulfate (50 Ag/ml) for penicillin and strep-
tomycin .
Sera and mAbs. Sera from HIV-1-infected individuals was
provided by the Boston City Hospital Immunodeficiency Clinic
and the Fenway Community Health Center, Boston, MA ; from
hepatitisB antigenic (HBsAg*)' individuals (Dr. Barbara Werner,
Massachusetts State Laboratory, Boston, MA); from HTLV1-
seropositive individuals (Dr . Antonella Caputo, Dana Farber Cancer
Institute, Boston, MA); and from patients with SLE (Dr . Paul
Demchak, New England Center Hospital, Boston, MA). Anti-
CD1mAb (OKT6 ascites) was a gift from Dr. Judith Swack, New
England Medical Center Hospital . Anti-intracellular adhesion mol-
ecule type 1 (ICAM-1) mAb (RR1/1) was provided by Dr . Tim-
othy Springer, Center for Blood Research, Boston, MA. Anti-
Leu-22 (CD43) and anti-Leu-3a (CD4) were purchased from Becton
Dickinson&Co . (Mountain View, CA). PE-conjugated OKT3
(CD3)waspurchased from Ortho Diagnostic Systems, Inc., West-
wood,MA .
Preparation ofAntibody-containing Eluates .
￿
The eluates were pre-
pared by incubating 1 ml of human serum (diluted 1:40 in PBS,
pH 7.2, containing 1% BSA and 0.2% sodium azide) with 10 9
SupT1 cells for 2hat 4°C. The cellswere washed four times with
40 ml of ice-cold PBS, and thebound antibodies were eluted using
2 ml of 0.1 M glycine, pH 2.5, for 2 min on ice . The cells were
removed by centrifugation (1,000 g), the eluates were neutralized
with 200 ptl of 1 M Tris, pH 8.0, and then dialyzed extensively
against PBS, pH 7.2, before use . Antibody concentration of the
eluates was determined by ELISA.
Immunofluorescence.
￿
For staining SupT1 cells, sera clarified by
centrifugation (10,000 g for 10 min) were diluted 1:50 in PBScon-
taining 1% BSAand 0.2% sodium azide (staining buffer) and in-
cubated for 30 min on ice with the SupT1 cells. After washing in
staining buffer, the cells were incubated for 30 min on ice with
FITC-conjugated goat anti-human IgG F(aV)Z (Tago Inc ., Burlin-
game, CA) diluted 1:60 in staining buffer. For staining thymocytes,
1 pg/ml anti-Leu-22 or 0.25 hg/ml ofhuman antibody-containing
eluate wasused, diluted in staining buffer. Binding of anti-Leu-22
was detected by FITC-conjugated goat anti-mouse IgG F(ab')a
(Tago Inc.), and binding of IgG from the eluates was detected by
thegoat anti-human IgG reagent described above. After staining,
all cells were washed in staining buffer, fixed in 1% formalin, and
analyzed on an Epics541 flow cytometer (Coulter Electronics Inc.,
Hialeah, FL).
Radiolabeling.
￿
SupT1 cells (2 x 10') or 4 x 10' thymocytes
or 5 x 106 COS cells were washed four times in PBS and
resuspended in 1 ml of PBS containing 10U of bovine milk lac-
toperoxidase (Calbiochem-Behring Corp., San Diego, CA) and 1
mCi of Na'21 I (Amersham Corp ., Arlington Heights, IL) . Then,
25 ul of 0.03% hydrogen peroxide was added to the cell suspen-
sion initially and at three successive times at 5-min intervals . So-
dium azide (25 pl ofa20% solution)wasadded to the cell suspen-
sions, the cells were washed four times in PBS, andthen solubilized
'Abbreviations used in thispaper: HBsAg*, hepatitis B antigenemic ; HTLV-1,
human Tlymphocyte virus type 1; ICAM-1, intracellular adhesion molecule
type 1 ; WA, Wiskott-Aldrich .
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in lysis buffer (0.05M Tris buffer, pH 7.2, containing 1% Triton
X-100 (Sigma Chemical Co .) and 1 mM PMSF. The cell lysates
were clarifiedby centrifugation (12,000gfor30 min), and the su-
pernatants were used for immunoprecipitations.
ImmunoprecipitationandGelElectrophoresis.
￿
Forimmunoprecip-
itation of radiolabeled cell lysates, aliquots were precleared with
protein A-Sepharose 6MBbeads (Pharmacia Fine Chemicals) and
then mixed with antibody (1 jug ofmAb or 0.25 of eluate) that
was prebound to 50 Al of packed beads. The mixtures were in-
cubated for 12-18 h at 4°C, the beads were washed six times with
lysis buffer, andthe immune complexes were eluted by heating for
5 min at 80°C in 2x sample buffer containing 50 mM Tris, pH
6.8, 4% SDS, 2% glycerol, 10% 2-ME and 0.02% bromphenol
blue dye .Theimmunoprecipitates were resolved by 10% SDS-PAGE,
and the dried gels were autoradiographed at -70°C for 5 d using
an intensifying screen . To prepare samples for theimmunoblotting
experiment, 6 x 10' SupT1 cells were solubilized in lysis buffer,
the lysates were clarifiedby centrifugation, and then precleared with
protein Abeads. Equal volume aliquots of the lysateswere immu-
noprecipitatedby anti-Leu-22 (1 NAg), anti-Leu-3a (1 p,g), or pooled
eluate (0.25 jug)prebound to protein A beads (50 Al) .The beads
were washed six times in lysis buffer, theimmune complexes were
eluted by heating in 2x sample buffer, and were resolved by 10%
SDS-PAGE .
Immunoblotting.
￿
Immunoprecipitates of unlabeled SupT1 cells
resolved by SDS-PAGE were blotted onto nitrocellulose paper as
described (22) . The nitrocellulose paper was blocked in 0.05 M
Tris-buffered saline, pH 7.0, containing 5% nonfat dry milk
(blocking buffer), and then reacted for 18 h at 4°C with anti-Leu-
22 (1 Ag/ml), diluted in blocking buffer. Theblot was washed ex-
tensively in blocking buffer and then reacted with alkaline phos-
phatase-conjugated goat anti-mouse Ig (BoehringerMannheim Bi-
ochemicals, Indianapolis, IN) diluted 1:600 in blocking buffer for
2 h at room temperature . After further extensive washing, theblot
was developed with a precipitating substrate (23) .
Glwosidase Treatment ofCells and Immunoprecipitates .
￿
Neuramin-
idase treatment of cells was performed in RPMI 1640 with 0.1
U/ml of enzyme at 37°C for 30 min . Enzyme digestions of im-
munoprecipitates were performed as follows : Vibrio cholera neur-
aminidase (Calbiochem-Behring Corp.), 0.1 Ft/ml for 60 min at
37°C ; O-Glycanase (Genzyme, Boston, MA), 4 mU/ml for 18 h
at 37°C . The enzyme reaction mixtures contained 0.17% SDS,
0.3% 2-ME, 1.25% NP-40, 5 mM calcium carbonate, 10 mM
phenanthroline, and 20 mM sodium cacodylate, pH 6 .5 .
Plasmid Construction and Cell Transfection .
￿
The PEER-3 cDNA
clone ofCD43 (providedby Dr. Minoru Fukuda, LaJolla, CA [24])
was subcloned into an expression vector(CDM8) that utilizes the
cytomegalovirus early promoter and contains simian virus40 origin
of replication (25) . The 1.5-kb PEER-3 cDNA was isolated from
Bluescript by digestionwith EcoRIandlow melting point agarose
gel electrophoresis.TherecoveredcDNA wasblunt ended using the
Klenow fragment ofDNA polymerase I, ligated to BstX1 linkers
and to BstX1-digestedCDM8. ADEAF-dextran method (25) was
used to transfect COS cells with the CD43-CDM8 plasmid .
Results
Detection ofAntiT Lymphocyte Antibodies in HIV1 + Sera.
To determine if antibodies to native T lymphocyte surface
antigens are produced by HIV-1-infected individuals, we
screened sera by immunofluorescent flow cytometry to iden-
tify those containing antibodies that could bind to aT cell
Anti-CD43 Autoantibodies in Human Immunodeficiency Virus 1 Infectionlymphoma line (termed SupTl) . This cell line was chosen
because it expresses multiple T cell antigens including high
levels ofCD4 (26). Sera from several HIV1-seropositive in-
dividuals contained antibodies that stained the SupT1 cell line
(Fig . 1) . In contrast, no sera from hepatitis B-antigenemic
individuals (HBsAg+) and few sera from individuals sero-
positive for human T lymphocyte virus type 1 (HTLV1) in-
fection or with the autoimmune disease SLE demonstrated
staining of SupT1 cells greater than sera from healthy, HIV
1-seronegative control subjects (Fig . 1) .
Identifcation ofCell Surface Protein Recognized byAnd-T Lym-
phocyte Antibodies . To identify the SupT1 surface antigen(s)
recognized by the serum antibodies, sera were absorbed to
SupTl cells, and the eluted antibodies (termed eluates) were
used to immunoprecipitate detergent-solubilized lysates from
surface 1251-labeled SupT1 cells. Of 18 eluates prepared from
different HIV1+ sera (sera also positive for SupT1 staining),
eight immunoprecipitated a single SupT1 surface protein with
aM of 120 kD on SDS-PAGE (Fig. 2 a). The 120-kD pro-
tein was not immunoprecipitated by eluates prepared from
the two HTLV1+ sera and the one SLE serum that did stain
the SupT1 cells . Thus, antibodies that immunoprecipitated
the 120-kD SupT1 protein were detected only in HIV1+
sera .
Biochemical Characterization of 120-kD SupF1 Protein .
￿
To
assess the contribution ofcarbohydrate to the 120-kD SupT1
protein, immunoprecipitates were subjected to glycosidase
digestion . Neuraminidase digestion of the immunoprecipi-
tated 120-kD SupTI protein shifted itsMr to -150 kD (Fig.
2 b, lane N), a result consistent with removal of negatively
charged sialic acid residues (18, 19) . Subsequent O-Glycanase
digestion of the neuraminidase-treated immunoprecipitate
resulted in a Mr of -110 W, indicating the presence of
0-linked oligosaccharides (Fig. 2 b, lane N/O) . Treatment
of the immunoprecipitated 120-kD protein with N-Glycanase
did not result in a discernable shift in relative molecular mass
of the protein (data not shown), suggesting that little or no
HIV-1 HBsAg HTLV-1
POSITIVE POSITIVE POSITIVE
(N=J0) (N=20) (N=27)
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N-linked oligosaccharides were present . These biochemical
characteristics suggested that the 120-kD SupT1 protein was
similar to CD43 (sialophorin, leukosialin), a cell surface
sialoglycoprotein predominantly expressed by cells of hema-
topoietic origin (19, 20) .
The 120-kDSupn Protein Is Identical to CD43.
￿
The results
oftwo experiments established that the 120-kD protein im-
munoprecipitated by the eluates isCD43 . First, an anti-CD43
mAb (anti-Leu-22; clone L60) (27) bound to the 120-kD SupT1
protein that was immunoprecipitated by pooled eluates, and
then electroblotted onto nitrocellulose paper (Fig. 2 c) . Second,
the eluates immunoprecipitated a 130-kD protein fromCOS
cells transfected with a cDNA clone encoding CD43 (Fig .
2 d, laneA) but not from controlCOS cells transfected with
a cDNA clone of ICAM-1 (Fig. 2 d, lane B) . anti-Leu-22
specifically immunoprecipitated a protein with aML of 120
kD from the COS cells expressing CD43 (Fig. 2 d, lane C),
suggesting that in transfected COS cells, anti-Leu-22 recog-
nizes a more sialylated form ofCD43 than that recognized
by the eluates.
Anti-CD43 Autoantibodies Bind Only to CD43 Expressed by
Thymocytes. To determine ifthe eluates could bind to normal
human cells ofT cell lineage known to express CD43, two
eluates (from two different HIV-1-infected subjects) containing
anti-CD43 antibodies were tested for binding to thymocytes,
fresh peripheral blood T lymphocytes, and PHA-activated T
lymphocytes that had been maintained in ID2. The eluates
bound only to thymocytes, whereas the anti-CD43 mAb (anti-
Leu-22) bound to all three cell types (Fig . 3 a) . However,
the eluates bound to all cell types if the cells were first treated
with neuraminidase, a treatment that eliminated the epitope
recognized by anti-Leu-22 (Fig. 3 b) . These results suggested
that the eluates recognize a non-sialic acid epitope ofCD43
present on both thymocytes and mature T lymphocytes, but
accessible to autoantibody binding only on thymocytes .
The eluates were also tested for binding to freshly obtained
peripheral blood T lymphocytes and T cell lines from HIV-
HIV-1
NEGATIVE
(N=14)
Figure 1 .
￿
Immunofluorescent screening of sera for
antibodies that could bind to the SupF1 T cell lym-
phoma line. Percent fluorescent cells indicates the per-
centage of cells stained by each serum (diluted 1:50)
greater than stained by buffer alone. Each dot
represents the percentage of cells stained by an in-
dividual serum . The horizontal dotted line indicates
3 SD above the mean percentage of cells stained by
sera from 14 healthy, individually tested, HIV-1
seronegative laboratory personnel.
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___-_____-_1-seropositive individuals (n = 3) . In all cases, the eluates
bound only to neuraminidase-treated cells (data not shown) .
These results suggest that peripheral blood T lymphocytes
from HIV-1-infected individuals either do not express par-
tially sialylated forms ofCD43, or if they do, are targeted
for rapid removal from the circulation.
Immunoprecipitation of cell lysates from radiolabeled
Figure 2 .
￿
Identification and char-
acterization of the SupT1 cell sur-
face protein recognized by the
human antibody-containing eluates .
(a) RepresentativeSDS-PAGE analysis oftheSupT1 surface proteinimmu-
noprecipitated by the human antibody-containing eluates . Antibodies :
normal human IgG, 1 ug (lane A) ; eluates from two different HIV-1- sera,
0.25 jig IgG (lanes B and C) ; eluates from two different HIV-1 * sera that
did not stain SupT1 cells, 0.25 ftg IgG (lanes D and E); eluates from four
different HIV-1 sera that did stain Sulfl cells, 0.25 hg IgG (lanes F-1);
anti-Leu-3a (Becton Dickinson & Co .) an anti-CD4 mAb, 1 hg (lanej);
an anti-CD1 mAb ascites, 1 ju1(lane K) . (b) Biochemical characterization
of the 120-kD SupTI protein . Three equal aliquots oflysates from radiola-
beled SupT1 cells were immunoprecipitated by 0.25 pg of pooled eluate
IgG (previously demonstrated to contain antibodies to the 120-kD SupT1
protein) and were then left undigested (-), digested with neuraminidase
(N), or digested with neuraminidase followed by O-Glycanase (N/0) and
analyzed by SDS-PAGE . (c) Immunoblot evidence that the 120-kD Su[Tl
protein is CD43 . Equal aliquots of a lysate prepared from 6 x 107 unla-
beled SupTI cells were immunoprecipitated by 0.25 ug of pooled eluate
IgG (eluate) ; by 0.5,ug ofanti-Leu-22 (BectonDickinson& Co.), an anti-
CD43mAb (Anti-Leu-22) ; orby 0.5 Rg ofanti-Leu-3a, an anti-CD4 mAb
used as a control (Anti-Leu-3A) . The immunoprecipitates were resolved
by SDS-PAGE under reducing conditions, electroblotted onto 0.45-/Am
nitrocellulose paper, and probed with anti-Leu-22 . (d) Immunoprecipita-
tion of CD43 from COS cells transfected with a cDNA clone encoding
CD43 . Separate sets ofCOS cells were transiently transfected using DEAE-
dextran with the CD43 cDNA clone PEER-3 inserted into the CDM8
plasmid vector, or with a control cDNA encoding ICAM-1 (43), also in-
serted into theCDM8 plasmid . 3 d later, each set of transfected cells was
surface iodinated, and cell lysates were immunoprecipitated by 0.25 Wg
pooled eluate IgG (lane A) or by 0 .5 ug of anti-Leu-22 (lane C) . Control
lysates from the radiolabeled ICAM-1 transfectants were immunoprecipi-
tated by 0.25 p.g of pooled eluate (laneB), by 0 .5 Fg of anti-Leu-22 (lane
D), or by 0 .5 Fig of RRl/1, an anti-ICAM-1 mAb (lane E) .
thymocytes confirmed that the anti-CD43 autoantibodies
recognize a partially sialylated form of CD43 . The pooled
eluates immunoprecipitated a single protein with a Mr of
-130 kD, whereas anti-Leu-22 immunoprecipitated a pro-
tein with a M, of -120 kD (Fig. 3 c, lanes A and B) . How-
ever, after digestion of each immunoprecipitate with neur-
aminidase, the proteins immunoprecipitated by the pooled
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The eluates identify a partially sialylated CD43 form expressed by normal thymocytes. (a) The eluates bind to thymocytes but not T
lymphocytes. Eluates from patients M-1 (shaded ban) and E-1 (black bars), and anti-Leu-22 (white bars) were tested by indirect immunofluorescence
for binding to thymocytes (thymus), peripheral blood T lymphocytes (T cells), and T lymphocytes stimulated with PHA for 3 d and maintained in
IL2 for 7 d (PHA-I1r2 T cells) . The results are representative of three separate experiments in which thymocytes and T lymphocytes from other donors
were tested . (b) The eluates bind to all cell types after cells are treated with neuraminidase (0.1 U/ml inRPMI 1640 for 30 min at 37°C), but reactivity
of anti-Leu-22 is lost . (c) Immunoprecipitation of CD43 from normal human thymocytes by the pooled eluates (lanesA and C) and anti-Leu-22 (lanes
B and D) . The immunoprecipitates in lanes C and D were treated with neuraminidase (0 .1 U/ml) before electrophoresis. 0 .5 Icg of pooled eluates
or 0 .5 kg of anti-Leu-22 were used to immunoprecipitate equal aliquots of 1251-labeled cell lysate from 4 x 10 7 normal thymocytes.
eluates, and anti-Leu-22 migrated identically with aM r of
150 kD (Fig . 3 c, lanes C andD) . These results are consistent
with those from the COS cell transfection experiments where
two forms ofCD43 were identified (Fig. 2 d), differing only
in their degrees of sialylation. Taken together with the im-
munofluorescence results, the data confirm that a partially
sialylated CD43 form is normally expressed on a large sub-
population of thymocytes but not on mature T lympho-
cytes (19) .
Discussion
These studies demonstrate that anti-CD43 autoantibodies
can be detected in sera from HIV-1 infected individuals and
that these autoantibodies bind to a form ofCD43 expressed
by normal thymocytes . The results also indicate that the au-
toantibodies recognize a CD43 epitope(s) on circulating T
lymphocytes that is masked by sialic acid residues. These char-
acteristics distinguish the anti-CD43 autoantibodies from an-
tilymphocyte antibodies described previously (2-9) that bind
circulating lymphocytes. The absence of partially sialylated
CD43 forms on circulating lymphocytes (19) suggests that
the anti-CD43 autoantibodies we detected could not con-
tribute to depletion of circulating CD4+/CD43+ lympho-
cytes . Rather, the thymocyte specificity of these antibodies
suggests that they may interfere with replenishment of the
circulating lymphocyte pool . Because anti-CD43 autoanti-
bodies were found only in HIV-1-infected individuals, it is
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possible that they are involved in the immunopathogenesis
of AIDS .
It has been demonstrated that binding ofmAbs to CD43
can induce biochemical and functional changes in T cells in
vitro. These antibody-mediated effects include induction of
phosphoinositide hydrolysis with resultant second messenger
formation (28) ; homotypic adhesion oflymphocytes (29) and
monocytes (30); and activation of thymocytes (31) and T lym-
phocytes (29, 32) by a mechanism independent ofTCR/CD3
complex-mediated signaling (28). It is plausible that the effects
mediated by anti-CD43 mAbs in vitro would be mirrored
byhuman anti-CD43 autoantibodies in vivo, resulting in in-
appropriate activation of thymocytes during the process of
maturation . Antibodies that can inappropriately activate or
cause adhesion of thymocytes may heighten thymocyte sus-
ceptibility to HIV-1 infection (33) or facilitate intercellular
virus transmission. Moreover, thymocyte-specific anti-CD43
antibodies could target thymocytes for destruction by com-
plement-mediated lysis and thus contribute to the severe thymic
atrophy in AIDS (34, 35). Ifthe thymus is required for normal
replenishment ofCD4+ lymphocytes in adult humans as it
is in adult mice (36, 37), then thymic dysfunction or destruc-
tion would be expected to prevent replenishment of mature
CD4+ cells killed by HIV-1 .
We observed that 8 of the 30 HIV1-seropositive subjects
tested (27%) had serum anti-CD43 antibodies that could im-
munoprecipitate CD43 from the SupT1 cells . Yet, 18 of the
30 HIV1-seropositive subjects (60%) had serum antibodies
that stained the SupT1 cell line (see Fig. 1) . Because somepatients may have had anti-CD43 antibodies that could not
immunoprecipitate CD43, we tested sera by immunofluores-
cence for the presence ofantibodies that could bind specifically
to transfectedCOS cells that express CD43 . By this method,
ser2 from 14 of the 30 HIV1-seropositive subjects (47%)
specifically stained the CD43-expressing COS cells (mean
fluorescence intensity of each positive sera > 3 SD above the
mean fluorescence intensity obtained using pooled normal
human sera) . No sera from HIV1-seronegative homosexual
men (n = 14) specifically stained the CD43-expressing cells .
These data suggest that- anti-CD43 autoantibodies are a
common feature of HIV-1 infection and provide further evi-
dence that such antibodies are restricted to individuals in-
fected by HIV-1 .
The most provocative data suggesting that anti-CD43 au-
toantibodies may contribute to the immunodeficiency ofAIDS
come from the study of children with the Wiskott-Aldrich
(WA) syndrome, an X chromosome-linked, severe im-
munodeficienry syndrome. Lymphocytes from children with
the WA syndrome express diminished amounts or unstable
forms ofCD43 (17, 38) . The clinical course of theWA syn-
drome includes progressive T cell depletion, susceptibility
to opportunistic and pyogenic infections, inability to pro-
duce antibodies against polysaccharide antigens, throm-
bocytopenia, and severe eczema (39) . Several of these clinical
features, particularly T cell depletion and susceptibility to
opportunistic infections, also characterize HIV-1 infection .
If normal CD43 expression is important for T cell develop-
References
ment and if anti-CD43 autoantibodies can interfere with this
process, then theremay be a link between the immunopatho-
genesis of AIDS and the WA syndrome.
Why are anti-CD43 autoantibodies produced by HIV-1-
infected individuals? One possibility is that in noninfected
individuals, immunogenic epitopes ofCD43 on circulating
lymphocytes evade immunologic recognition because they are
masked by sialic acid residues . However, in conditions where
increased lymphocyte destruction is thought to occur (e.g.,
HIV-1-induced lymphocyte cytopathicity), autoimmunogenic
CD43 epitopes may be exposed. The exposure of such epi-
topes could result in the induction of autoantibodies, before
CD4+ lymphocyte depletion and the corresponding defect
in humoral immune responses occur.
Depletion ofCD4+ lymphocytes has been noted in many
HIV1-seropositive, healthy individuals (40) when the propor-
tion of virus-infected lymphocytes is estimated to be small
("1:50,000) (41) and plasma viremia is low or undetectable
(41, 42) . Such observations support the notion that in addi-
tion to direct virus cytopathicity, other mechanismsmay con-
tribute to CD4+ lymphocyte depletion early in the course
ofHIV-1 infection . For example, cytolysis of infected CD4+
cells in asymptomatic individuals by CTL combined with
defective T cell replenishment could manifest as a selective
depletion of theCD4+ lymphocyte pool . Understanding the
effects of anti-CD43 autoantibodies on T cell maturationmay
provide further insight into the immunopathogenesis of
CD4+ cell depletion in AIDS .
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